ReviewThe Lancet regional health. Western Pacific2025
Risk-adjusted breast screening: an Australian perspective and considerations for the Western Pacific.
Review in The Lancet regional health. Western Pacific, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- GP perspectives on genomics in primary care: a qualitative study on using polygenic risk scores to evaluate cancer risk.The British journal of general practice : the journal of the Royal College of General Practitioners · 2026Article
- Key stakeholders' perspectives on implementation of risk-based population breast cancer screening in Australia - "We can either get on the bus or get under it".Archives of public health = Archives belges de sante publique · 2025Article
- Recent advances in breast cancer screening and treatment in the Western Pacific: challenges and opportunities.The Lancet regional health. Western Pacific · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most common cancer in females globally, and the leading cause of female cancer deaths. The 2023 World Health Organisation Global Breast Cancer Initiative Framework aims to prevent 2·5 million deaths from breast cancer by 2040. Early detection of breast cancer is central to this goal, and population-based breast screening is key to early detection. A more risk-adjusted approach to screening within current target age ranges, whether risk-stratified (tailoring population-wide screening protocols based on risk) or risk-targeted (prioritising available screening services to higher risk females) is likely to prevent further deaths. This article presents a review of the risk-adjusted screening initiative in Australia (the Roadmap to Optimising Screening in Australia (ROSA) Project) and explores a potential framework for advancing risk-adjusted strategies for breast screening throughout the Western Pacific region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.